Eli Lilly and Company (NYSE: LLY) has climbed 37 positions over the past month to rank 76th out of 503 in the Favored Green Zone of the SIA S&P 500 Index Report. Its SIA SMAX Score stands at 8/10. The monthly ranking improvement contrasts with a decline of 50 positions over the past quarter, indicating that recent relative-strength gains have only partly reversed the earlier deterioration.
The latest Point & Figure signal is a Double Top. Resistance stands at $1282.06, followed by potential resistance at $1415.50 and all-time-high resistance at $1502.14. Near-term support lies at the 3-box reversal level of $1138.44, with additional support at $1094.23 and $933.91.
The Drugs sector ranks second out of 31 sectors in the SIA Sector Report’s Favored Green Zone. Both the sector and LLY therefore hold Favored Green Zone classifications in their respective reports, although the stock’s quarterly ranking decline tempers its more recent improvement.
LLY gained 10.17% over the past month, 8.36% over the quarter and 17.03% year to date, outperforming the S&P 500 Index Fund’s respective returns of 0.40%, 1.32% and 14.02%. The quarterly benchmark outperformance sits alongside a decline in SIA report ranking, highlighting the distinction between performance against a single benchmark and relative positioning within the report.
The monthly ranking recovery, Double Top signal and SIA SMAX Score of 8/10 present a constructive technical picture, while the quarterly ranking setback remains a counterpoint. These readings form part of the broader assessment of portfolio objectives and risk.
Eli Lilly and Company is an Indianapolis-based global pharmaceutical company founded in 1876, operating across approximately 90 countries. Its business spans Cardiometabolic Health, Oncology, Immunology and Neuroscience, with products including Mounjaro, Zepbound, Verzenio, Taltz, Kisunla and Emgality.
Disclaimer: SIACharts Inc. specifically represents that it does not give investment advice or advocate the purchase or sale of any security or investment whatsoever. This information has been prepared without regard to any particular investors investment objectives, financial situation, and needs. None of the information contained in this document constitutes an offer to sell or the solicitation of an offer to buy any security or other investment or an offer to provide investment services of any kind. As such, advisors and their clients should not act on any recommendation (express or implied) or information in this report without obtaining specific advice in relation to their accounts and should not rely on information herein as the primary basis for their investment decisions. Information contained herein is based on data obtained from recognized statistical services, issuer reports or communications, or other sources, believed to be reliable. SIACharts Inc. nor its third party content providers make any representations or warranties or take any responsibility as to the accuracy or completeness of any recommendation or information contained herein and shall not be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. Any statements nonfactual in nature constitute only current opinions, which are subject to change without notice.
